Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01594216
Title Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania

estrogen-receptor positive breast cancer


Exemestane + Ruxolitinib

Age Groups: adult
Covered Countries USA

No variant requirements are available.